Core Viewpoint - Barclays has significantly reduced its peak sales forecast for Novo Nordisk's obesity drug CagriSema from $12 billion to $2 billion due to disappointing trial results [1][2]. Group 1: Sales Forecast and Market Impact - The reduction in sales forecast indicates a substantial setback for Novo Nordisk in its competition against U.S. rival Eli Lilly in the obesity market [2]. - Novo's late-stage trial data revealed that CagriSema underperformed compared to Eli Lilly's Zepbound, which launched in late 2023, with Zepbound showing better weight loss results than previously reported by Lilly [3]. - Following the announcement, Novo's shares fell by 16%, erasing gains from its successful weight-loss drug Wegovy, while Eli Lilly's shares increased by 5% [3]. Group 2: Future Prospects and Analyst Sentiment - Novo plans to launch CagriSema next year, anticipating U.S. FDA approval by the end of this year; however, analysts from Barclays, Jefferies, and others express doubts about the drug's commercial viability based on the recent data [4].

Starting the last week of trading in February on an inauspicious note, NuScale Power (NYSE: SMR) stock is tumbling lower today. With Barclays expressing a more bearish stance on shares of the advanced nuclear reactor designer, investors seem less inclined to maintain their positions. As of 2:15 p.m. ET, shares of NuScale Power are down 8.1%, paring back an earlier loss of 9.9%. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indisp ...

AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential On February 20, Barclays began coverage of AbbVie Inc. (NYSE:ABBV) with an Overweight rating. It set a price target of $275 on the stock. The firm said current consensus estimates do not fully reflect AbbVie’s operating leverage potential. In its note, Barclays added that positive results from any of the company’s proof-of-concept s ...

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. Barclays Begins Coverage on Eli Lilly (LLY), Sees Strong Position in Obesity Market On February 20, Barclays initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Overweight rating. The firm set a $1,350 price target on the stock. The firm said GLP-1 weight loss treatments represent a “durable structural shift,” reflecting growing confidence in the long-term demand for these therapies. The ...

Industry Overview - The Zacks Foreign Banks Industry includes overseas banks operating in the U.S., supervised by the Federal Reserve, providing a range of financial services to both individual and corporate clients [3] - The industry has been undergoing restructuring to improve efficiency, focusing on higher-growth segments like wealth management and digital platforms [4][5] Key Themes Influencing the Industry - Continued restructuring efforts are enhancing revenue quality and improving net interest margins, leading to more stable fee-based income streams [4][5] - Lower interest rates from central banks are expected to stimulate borrowing and reduce funding costs, supporting banks' top-line growth [6] - The uneven global economic recovery post-COVID is limiting growth potential, with weak economic performance in some regions affecting profitability [7] Performance Metrics - The Zacks Foreign Banks Industry ranks 23, placing it in the top 9% of over 250 Zacks industries, indicating strong near-term outperformance potential [8][9] - The industry has collectively surged 93% over the past two years, outperforming the S&P 500 and the Zacks Finance Sector [11] Valuation Insights - The industry has a trailing 12-month price-to-tangible book ratio (P/TBV) of 3.45X, significantly lower than the S&P 500's 11.91X, indicating a discount compared to the broader market [15][18] Company Highlights HSBC - HSBC has $3.23 trillion in assets and is focusing on expanding operations in Asia, particularly in wealth management [21] - The bank is winding down non-core operations in various regions while enhancing its presence in Asia and the Middle East [23] - HSBC's shares have risen 35.2% in the past six months, with a Zacks Rank of 2 (Buy) [25] Itau Unibanco - Itau Unibanco is expanding its operations through strategic acquisitions and has a strong presence in Brazil and other Southern Cone countries [28][30] - The bank's shares have gained 42.6% in the past six months, with a Zacks Rank of 2 (Buy) [33] Barclays - Barclays has £1,544.2 billion ($2,106.3 billion) in total assets and is focusing on core businesses through targeted acquisitions and partnerships [36] - The bank's shares have increased by 27.4% in the past six months, with a Zacks Rank of 1 (Strong Buy) [40]

Amgen Inc. (NASDAQ:AMGN) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate On February 20, Barclays initiated coverage of Amgen Inc. (NASDAQ:AMGN) with an Equal Weight rating and a $185 price target. The analyst said there is still “plenty of time” before the Phase 3 MARITIME trial results are released, which means the “biggest source of debate” around Amgen will remain unresolved for now. The firm also note ...

Core Insights - KKR & Co. Inc. has seen significant changes in institutional ownership, with several hedge funds increasing their positions dramatically in the third quarter of the year [1][6] - Insider trading activity indicates confidence in the company's future, with both the Director and CEO purchasing substantial shares [2] - Analysts have mixed but generally positive outlooks on KKR's stock, with upgrades and downgrades from various firms [3][4] Institutional Ownership - Covenant Asset Management LLC increased its holdings by 1,424.8%, now owning 29,826 shares valued at $3,876,000 after acquiring 27,870 shares [1] - Cumberland Partners Ltd raised its position by 816.2%, owning 25,791 shares worth $3,352,000 after acquiring 22,976 shares [1] - Allen Investment Management LLC increased its position by 165.0%, now holding 247,375 shares valued at $32,146,000 after acquiring 154,009 shares [1] - Stonegate Investment Group LLC purchased a new position valued at approximately $6,219,000 [1] - Generali Asset Management SPA SGR boosted its position by 132.5%, now owning 37,323 shares valued at $4,850,000 after purchasing 21,270 shares [1] - Institutional investors currently own 76.26% of KKR's stock [1] Insider Transactions - Director Matt Cohler acquired 43,872 shares at an average cost of $102.90 per share, totaling $4,514,428.80, representing a 2,733.46% increase in his position [2] - CEO Scott C. Nuttall purchased 125,000 shares at an average price of $102.66 per share, totaling $12,832,500, resulting in a 0.81% increase in his holdings [2] - Insiders have collectively bought 343,872 shares worth $35,367,179 over the last three months, with insiders owning 39.34% of the company's stock [2] Analyst Ratings - HSBC upgraded KKR from a "hold" to a "buy" rating with a price target of $144.00 [3] - Barclays lowered its price target from $159.00 to $136.00 while maintaining an "overweight" rating [3] - Wall Street Zen upgraded KKR from a "sell" to a "hold" rating [4] - Oppenheimer reduced its price target from $190.00 to $187.00, maintaining an "outperform" rating [4] - UBS Group lowered its target price from $168.00 to $125.00 while keeping a "buy" rating [4] - The average rating for KKR is "Moderate Buy" with an average target price of $153.50 [4] Financial Performance - KKR reported a quarterly EPS of $1.12, missing estimates of $1.14, with revenue of $5.93 billion, significantly exceeding expectations of $2.23 billion [7] - The company's quarterly revenue increased by 76.1% compared to the same quarter last year [7] - KKR's net margin stands at 11.97% and return on equity at 5.77% [7] Dividend Information - KKR announced a quarterly dividend of $0.185, with an annualized dividend of $0.74 and a yield of 0.7% [8] - The dividend payout ratio is currently 31.62% [8] Company Overview - KKR & Co. Inc. is a global investment firm specializing in private markets and alternative asset management, founded in 1976 [9] - The firm operates across various sectors including private equity, credit, real assets, growth equity, and hedge fund strategies [9][10]

AMG National Trust Bank trimmed its holdings in shares of Barclays PLC (NYSE:BCS – Free Report) by 25.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,286 shares of the financial services provider’s stock after selling 26,421 shares during the period. AMG National Trust Bank’s holdings in Barclays were worth $1,639,000 at the end of the most recent reporting period. Get Barclays alerts: Several other large investors h ...

Ralliant Corporation (NYSE:RAL) is among the 11 Newly-Listed NYSE Stocks to Buy Now. Barclays Lowers its Price Target on Ralliant Corporation (RAL) to $52 and Maintains an Overweight Rating On February 9, 2026, Barclays lowered its price target on Ralliant Corporation (NYSE:RAL) to $52 from $60 and maintained an Overweight rating, stating that the company delivered a potentially “thesis-changing” quarter. On February 6, 2026, Morgan Stanley analyst Christopher Snyder reduced the price target to $45 from ...

ON Semiconductor Corporation (NASDAQ:ON) is among the 12 Best Tech Stocks that Beat Earnings Estimates. On February 12, 2026, Barclays analyst Tom O’Malley initiated coverage of ON Semiconductor Corporation (NASDAQ:ON) with an Equal Weight rating and a $75 price target. Tom O’Malley said Barclays is “cautiously optimistic” on an industrial recovery as PMIs turn higher but recommends a selective approach, noting each company “faces at least one unique challenge.” He added that On Semi’s high China and auto ...